Phase II trial of capecitabine + bevacizumab as maintenance treatment after initial treatment with XELOX in previously untreated metastatic colorectal cancer

ABSTRACT: Interventions: Patients receive XELOX(+BEV) for 4 cycles, they then receive XEL+BEV until PD, they finally receive XELOX(+BEV) until PD. Primary outcome(s): Duration of disease control Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2621545 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR